Aptevo Therapeutics
APVO
1 hedge funds and large institutions have $8.62M invested in Aptevo Therapeutics in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
16% more capital invested
Capital invested by funds: $7.44M → $8.62M (+$1.19M)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sessa Capital
New York
|
-$106K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$55K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$41K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$37K |
| 5 |
CL
CSS LLC
Chicago,
Illinois
|
-$36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | – | – | – |
|
27
Morgan Stanley
New York
| $6K | – | – | – |
|
|
PA
28
Parallel Advisors
San Francisco,
California
| $5K | – | – | – |
|
|
TRSOTSOK
29
Teachers Retirement System of the State of Kentucky
Frankfort,
Kentucky
| $4K | – | – | – |
|
30
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $1K | – | – | – |
|
|
QI
31
QS Investors
New York
| $1K | – | – | – |
|
|
ARTA
32
A.R.T. Advisors
New York
| – | -$41K | – | – |
|
33
BNP Paribas Financial Markets
Paris,
France
| – | -$4 | – | – |
|
|
BCM
34
Bridgeway Capital Management
Houston,
Texas
| – | -$55K | – | – |
|
|
CL
35
CSS LLC
Chicago,
Illinois
| – | -$36K | – | – |
|
|
36
Dimensional Fund Advisors
Austin,
Texas
| – | -$37K | – | – |
|
|
HKAM
37
Horizon Kinetics Asset Management
New York
| – | -$22K | – | – |
|
|
SC
38
Sessa Capital
New York
| – | -$106K | – | – |
|
39
Victory Capital Management
San Antonio,
Texas
| – | -$4K | – | – |
|
APVO Hedge Fund Activity: Q4 2019 in Review
1 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q4 2019, worth a combined $8.62M — up 16% from $7.44M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new APVO positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $4.98M. The largest seller was Sessa Capital, cutting an estimated $106K.
- 1 institutional investor held Aptevo Therapeutics (APVO) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $8.62M of Aptevo Therapeutics stock for Q4 2019, up 16% quarter-over-quarter.
- 1 fund opened new Aptevo Therapeutics positions in Q4 2019 and 0 closed out, a net change of +1 holder.
- The largest Aptevo Therapeutics buyer in Q4 2019 was Stonepine Capital Management, an estimated $4.98M added.
- The largest Aptevo Therapeutics seller in Q4 2019 was Sessa Capital, an estimated $106K sold.
Based on aggregated 13F filings for Q4 2019.